Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03167411 · ClinicalTrials.gov registry record · Phase 1

Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

A Phase 1 study of Type2 Diabetes Mellitus, sponsored by Theracos.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT03167411 is a Phase 1 study of Type2 Diabetes Mellitus that has completed, run by Theracos. The registered enrollment target is 20 participants, below the 7,065-participant average among 7 other Type2 Diabetes Mellitus trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03167411, a Phase 1 study of Type2 Diabetes Mellitus, has completed, sponsored by Theracos.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine the drug-drug interaction when given the study drug, bexagliflozin, with one of the most commonly prescribed glucagon-like peptide 1 receptor agonist (GLP-1 RA) exenatide. The study will also evaluate how safe the study drug is and how well the study drug is tolerated when administered with exenatide injection.

Conditions Studied

Type2 Diabetes Mellitus

Interventions

  • DRUG Bexagliflozin
  • DRUG Exenatide Injection

Study Locations (1)

Indiana

  • Clinical Research Site - Evansville

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2017-05-24
Est. Completion 2017-06-29
Phase Phase 1

Sponsor

Theracos

18 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03167411

The ClinicalTrials.gov registry entry for NCT03167411 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,065-participant average among 7 other Type2 Diabetes Mellitus trials with a reported enrollment target (100% lower). The listed sponsor is Theracos, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Bexagliflozin is the first listed.

NCT03167411 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT03167411 about?

NCT03167411 is a clinical study titled "Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection". The purpose of this study is to examine the drug-drug interaction when given the study drug, bexagliflozin, with one of the most commonly prescribed glucagon-like peptide 1 receptor agonist (GLP-1 RA) exenatide. The study will also evaluate how safe the study drug is and how well the study drug is t...

What is the current status of trial NCT03167411?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-05-24. Estimated completion is 2017-06-29.

What conditions does trial NCT03167411 study?

This clinical trial studies the following conditions: Type2 Diabetes Mellitus.

What interventions are being tested in trial NCT03167411?

The interventions under investigation include: Bexagliflozin (DRUG), Exenatide Injection (DRUG).

Who is sponsoring clinical trial NCT03167411?

This trial is sponsored by Theracos, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03167411 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type2 Diabetes Mellitus

All registered trials for this condition

Indiana

All trials with a study site in Indiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.